Xenon Pharmaceuticals Inc. (XENE) Stock Price & Analysis

Xenon Pharmaceuticals Inc. (XENE) rose 3.09% to USD 52.79 as of June 10, 2026 at 03:45 UTC, according to Nexqual real-time market data.

XENE last closed at USD 51.21; the session ranged USD 51.33–52.87 on volume of 1,417,069 shares. Market capitalization is $5.10B, with a 52-week range of USD 30–63.95 (NGM). Source: Nexqual, June 10, 2026 at 03:45 UTC.

Key Statistics (as of June 10, 2026 at 03:45 UTC)

Technical Analysis (XENE)

Nexqual's technical model rates XENE "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:45 UTC.

Analyst Ratings (XENE)

Wall Street analysts rate XENE "Strong Buy" based on 19 analysts, with a mean price target of USD 79.3 (range USD 56–100), per Nexqual as of June 10, 2026 at 03:45 UTC.

Earnings (XENE)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 03:45 UTC.

Financials & Fundamentals (XENE)

Source: Nexqual, June 10, 2026 at 03:45 UTC.

Financial Health Score (XENE)

Nexqual rates Xenon Pharmaceuticals Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:45 UTC.

Ownership (XENE)

Source: Nexqual, June 10, 2026 at 03:45 UTC.

Leadership (XENE)

Xenon Pharmaceuticals Inc. is led by Ian C. Mortimer C.M.A. (age 49), President, CEO & Director, per Nexqual as of June 10, 2026 at 03:45 UTC.

Major Backers & Investors (XENE)

Notable institutional backers of Xenon Pharmaceuticals Inc. include FMR, LLC, Fidelity, Avoro Capital Advisors LLC, according to Nexqual as of June 10, 2026 at 03:45 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 03:45 UTC.

From Xenon Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our product candidates that are in clinical development may compete with various therapies and drugs, both in the marketplace and currently under development.     12   If one or more of our proprietary or partnered product candidates is approved for the treatment of epilepsy, we anticipate that they could potentially compete with other anti-seizure medications, or ASMs, or one another.
• If one or more of our proprietary product candidates were approved for the treatment of MDD, we anticipate that they could potentially compete with other anti-depressant medications, or ADs.
• While we believe that our technology, development experience, scientific knowledge and drug discovery approach provide us with certain advantages, we face potential competition in our discovery and product candidate development efforts from many different approaches and sources, including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions.

Partnerships

• Pursuant to our collaboration with Neurocrine Biosciences, Neurocrine Biosciences controls the prosecution, maintenance and other matters relating to some of the patent portfolio for the selective Nav1.6 inhibitors and dual Nav1.2/1.6 inhibitors subject thereto, although we have a right to comment.
• Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:45 UTC. This page is informational and not investment advice.